EXOZ
eXoZymes Inc. Common StockEXOZ
EXOZ
About: EXoZymes Inc is focused on using a biomanufacturing platform to create valuable biochemicals, including Active Pharmaceutical Ingredients or APIs, biofuels, food flavors, and cosmetics, offering a sustainable alternative to traditional chemical production methods.
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
1.21% more ownership
Funds ownership: 0% [Q3] → 1.21% (+1.21%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for EXOZ.
Financial journalist opinion
Based on 5 articles about EXOZ published over the past 30 days
Neutral
GlobeNewsWire
3 days ago
Bringing clarity and precision to the cell-free space by introducing exozymes
Scientific definition of exozymes featured as cover story in GEN Biotechnology, freely available as an Open Access paper The author team introduces the terms ‘exozymes' to bring clarity to the rapidly evolving field of cell-free biomanufacturing—a biomanufacturing method to produce chemicals without relying on living cells like bacteria or yeast The paper features co-authors from multiple institutions such as The National Renewable Laboratory (NREL), UCLA, Caltech, University of Colorado Boulder, Sepia Biosciences, as well as the venture studio, Ferment The authors intend the terms to be freely available for use by the broader scientific community, and no trademarks have been filed Monrovia, CA, April 21, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - is featured as the cover story in the April issue of the peer-reviewed journal, GEN Biotechnology. Dr. Tyler Korman, co-founder and VP of Research at eXoZymes, is excited about the 'exozymes' cover story in GEN Biotechnology, which is freely available as an Open Access paper The Perspective paper called “Exozymes for Biomanufacturing: Toward Clarity and Precision in the Cell-Free Space” focuses on providing a scientific definition of 'exozymes' to alleviate confusion surrounding use of the phrase 'cell-free' with an emphasis on its use in biomanufacturing.

Neutral
GlobeNewsWire
2 weeks ago
BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant
Monrovia, CA, April 10, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced its latest initiative - BioClick - a pioneering concept designed to enhance and accelerate the engineering of enzymes for advanced chemical reactions. Funded in part by a $300K grant from the National Institutes of Health (NIH), this project has the potential to revolutionize how medicines and other bio-based compounds are created.

Neutral
GlobeNewsWire
3 weeks ago
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO
Expanded leadership team as eXoZymes ramps up commercial growth Damien Perriman brings more than two decades of experience in successfully developing and commercializing novel biotechnologies Focus on developing commercial opportunities, spin-outs, joint-ventures, and licensing deals with future partners Monrovia, CA, April 02, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - announced the appointment of Damien Perriman to a newly created role as Chief Commercial Officer (CCO). Perriman brings more than two decades of experience in successfully commercializing several biotechnologies, spanning diverse markets such as nutrition, personal care, plastics, textiles, fragrances, performance fuels, and specialty chemicals.

Neutral
GlobeNewsWire
3 weeks ago
eXoZymes Provides Fourth Quarter and Full Year 2024 Update
Management to Host Conference Call Today at 4:30PM Eastern

Neutral
GlobeNewsWire
4 weeks ago
eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025
Monrovia, CA , March 26, 2025 (GLOBE NEWSWIRE) -- eXoZymes Inc. (NASDAQ: EXOZ) [“eXoZymes”] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - plans to host a webinar on Wednesday, April 2, 2025 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and full year 2024. A press release detailing these results will be issued prior to the call.

Charts implemented using Lightweight Charts™